Kolmar BioTech콜마바이오텍
215380 · KOSDAQ · ₩215380 · 콜마바이오텍
- Market cap
- ₩35B
- Enterprise value
- ₩53B
- P/E
- 28.6×
- P/B
- 1.3×
- Dividend yield
- 0.0%
- ROE
- 4.6%
- Net margin
- 2.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−53.7% from the high
₩1,707Today: ₩2,030 – ₩2,110₩4,535
Returns
- 1W−4.1%
- 1M−8.1%
- 3M−13.9%
- 6M−30.3%
- YTD+19.3%
- 1Y+14.9%
- Volume today
- 23,926
- 0.2× the 20-day average
- Traded today
- ₩50M
- Listed shares
- 16,829,576
- EPS (12 months)
- ₩73
- Earnings yield 3.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumFlat-2.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Kolmar BioTech stock overview
Kolmar BioTech (콜마바이오텍, KRX: 215380) is listed on KOSDAQ, in the Biotech & Pharma sector. Its shares closed at ₩2,100 on Oct 27, 2026, up 3.45% on the day, giving it a market value of ₩35B.
Key facts
- Market cap
- ₩35B
- Sector
- Biotech & Pharma
- Latest price change
- +3.45%
- As of
- Oct 27, 2026
Quick answers about Kolmar BioTech
- What is the market cap of Kolmar BioTech?
- The market capitalisation of Kolmar BioTech was ₩35B at the close on Oct 27, 2026.
- Who are the largest shareholders of Kolmar BioTech?
- According to the latest official filings, the largest reported holders are Colmar Holdings (64.73%, as of Apr 3, 2026); Cheon Hee-jung (33.61%, as of Mar 10, 2026); Cheon Se-jeong (12.73%, as of Aug 28, 2025).
- When is the next earnings report from Kolmar BioTech?
- Korean companies rarely announce results dates in advance. Based on when Kolmar BioTech filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Loading data for this company — check back soon
- Korean name
- 콜마바이오텍
- Sector
- Biotech & Pharma
- Business group
- Kolmar
- CEO
- 문병석
- Founded
- Feb 2015
- Listed
- May 2015
- Listed shares
- 16,829,576
- Fiscal year ends
- Month 12
- Website
- kolmarbiotech.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Merger Completion Report (Merger)Sep 22, 2026
- Adjustment of Conversion PriceAug 31, 2026
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 28, 2026
- Other management mattersAug 19, 2026
- Change of Department AffiliationAug 14, 2026
Titles in Korean until English translations are added.
Also known as: Kolmar BioTech / 콜마바이오텍 / 215380 / KRX:215380
Source: KRX statistical information